Depression

According to the authors, being able to identify mood disturbances through passive digital biomarker data can be promising in next-generation predictive, personalized mental health diagnostics.

Using the term "pseudodementia" contributes to the mismanagement and mistreatment of the disease.

Additionally, the authors are concerned by the lack of increase in depressive or anxiety diagnoses, indicating potential barriers to care.

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

Zuranolone enhances health care providers’ ability to address the complex needs of patients with PPD, offering new hope for rapid and sustained relief from depressive symptoms.

Patients with MDD may also seek complementary or alternative therapies in the form of dietary supplements which might be perceived by patients to be natural and safer than medicinal agents.

The findings also demonstrate that body dysmorphic disorder is also associated with high levels of comorbid psychopathology, risk, and psychosocial impairment.

However, the cost of zuranolone makes it challenging to access and justify, given study results comparing it with brexanolone.

The authors note that the oral, at-home treatment can be a better alternative for patients by reducing inconveniences that come with the injectable and nasal administration methods.

The American College of Clinical Gynecology recommends consideration of brexanolone or zuranolone in postpartum patients with onset of moderate-to-severe perinatal depression in the third trimester or within 4 weeks postpartum.

The findings suggest that exploring gender identity is a normal part of adolescent development for some youths.

Perinatal depression increases the risk of cardiovascular disease in women.

At ASHP Pharmacy Futures 2024, Mei T. Liu, PharmD, BCPP, highlights the global prevalence and multifaceted nature of depression, its bidirectional relationship with medical conditions, and the need for diverse, evidence-based treatment options.

The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.

Experts emphasize the importance of awareness when using social media and make suggestions on how to combat the spread of misinformation and conspiracy theories.

Despite the finding, the authors suggest further research is done to better understand the mechanisms behind the interactions between asthma, sleep, and depression.

The survey reported that approximately 65% of participants were concerned about their mental health, which is a 15% increase since 2020.

The story of gepirone may spark new conversations for industry standards on drug development to facilitate future innovations.

A new treatment for postpartum depression has been developed with rapid onset, cutting down the time it has taken previous treatments to take effect by weeks or months.

Compared with women who aren’t experiencing menopausal symptoms, women in the perimenopause stage were approximately 40% more likely to experience depressive symptoms.

This expansion of their role goes beyond traditional dispensing duties, positioning pharmacists as an essential bridge between patients and the broader health care system.

However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.

Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.

Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

Case reports have shown a potential association with adverse psychological effects.